Castro Elena, Figliuzzi Rhett, Walsh Sarah, Craigie Samantha, Nazari Jonathan, Niyazov Alexander, Samjoo Imtiaz A
Hospital Universitario 12 de Octubre, Unidad C. Cáncer Genitourinario, Sistema Nervioso Central, Sarcomas y Tumores Cutáneos, 28041 Madrid, Spain.
EVERSANA, Value & Evidence, Burlington, ON L7N 3H8, Canada.
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyae321.
Despite being an important goal, the preservation of quality of life of patients with metastatic castration-resistant prostate cancer (mCRPC) is poorly characterized across lines of therapy. In this review, a systematic literature review and meta-analysis were conducted to synthesize EuroQoL 5-Dimension (EQ-5D) data among adult men with asymptomatic or mildly symptomatic mCRPC in both first line (1L) and second line and later (2L+) therapy. MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to October 2022 using Ovid. Supplemental searches of other data sources were also conducted (PROSPERO registration: CRD42021283512). Meta-analyses were conducted to estimate pooled EQ-5D index utility values and EQ visual analog scale (VAS) scores in both 1L and 2L+. Various sensitivity analyses were also conducted. Forty-five unique publications met the inclusion criteria. In primary studies, baseline EQ-5D index utility values ranged from 0.7 to 0.9 in 1L and 0.63 to 0.7 in 2L+. Twelve trials and observational studies were feasible for inclusion in the meta-analysis. The pooled mean baseline EQ-5D index utility value was estimated as 0.79 (95% CI, 0.70-0.84) and 0.69 (95% CI, 0.67-0.71) for 1L (n = 7 studies) and 2L + (n = 4 studies), respectively. The pooled mean baseline EQ VAS score was estimated as 74.63 (95% CI, 70.97-78.29) and 65.82 (95% CI, 64.53-67.11) in 1L and 2L+, respectively. Limitations include hampered comparability between studies due to heterogeneity in study design and geographical regions. This study provides a comprehensive synthesis of EQ-5D data presently available in adults with mCRPC in both 1L and 2L + therapy.
尽管这是一个重要目标，但转移性去势抵抗性前列腺癌（mCRPC）患者生活质量的维持在各治疗线中的特征描述并不充分。在本综述中，我们进行了一项系统的文献综述和荟萃分析，以综合无症状或轻度症状的成年男性mCRPC患者在一线（1L）和二线及后续（2L+）治疗中的欧洲五维健康量表（EQ-5D）数据。使用Ovid从数据库建库至2022年10月对MEDLINE、Embase和Cochrane CENTRAL进行了检索。还对其他数据源进行了补充检索（PROSPERO注册号：CRD42021283512）。进行荟萃分析以估计1L和2L+治疗中汇总的EQ-5D指数效用值和EQ视觉模拟量表（VAS）评分。还进行了各种敏感性分析。45篇独特的出版物符合纳入标准。在初步研究中，1L治疗的基线EQ-5D指数效用值范围为0.7至0.9，2L+治疗的范围为0.63至0.7。12项试验和观察性研究可纳入荟萃分析。1L（n = 7项研究）和2L+（n = 4项研究）的汇总平均基线EQ-5D指数效用值分别估计为0.79（95% CI，0.70 - 0.84）和0.69（95% CI，0.67 - 0.71）。1L和2L+治疗中汇总的平均基线EQ VAS评分分别估计为74.63（95% CI，70.97 - 78.29）和65.82（95% CI，64.53 - 67.11）。局限性包括由于研究设计和地理区域的异质性，研究之间的可比性受到影响。本研究全面综合了目前1L和2L+治疗的成年mCRPC患者中可用的EQ-5D数据。
